Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 42 |
| Active Pipeline (Recruiting Now) | 21 (9) |
| Completed vs Stopped Early | 11 / 5 (11.9%) |
| Median Closed Actual Enrollment | 34 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Chu Toulouse | Toulouse | 7 |
| Institut Paoli-Calmettes | Marseille | 3 |
| CHU Nantes | Nantes | 3 |
Explore interactive annual charts and M&A subsidiary rollups in the University Hospital, Toulouse Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.